Cayer Paul E

Avg. Two Year Performance

No purchase track record

78% Avg. Sale Return

33% Compound

	1 Mo	3 Mo	6 Mo	1 Yr	2 Yr
Average Purchase Return	--	--	--	--	--
Purchase Success Rate	--	--	--	--	--
Average Sale Return	10%	32%	47%	34%	78%
Sale Success Rate	2 of 4	2 of 4	3 of 4	3 of 4	3 of 4

Otonomy, Inc.

Drugs » Biotechnology

President and CFBO:

Holdings: 183.73K shares

Sentiment

Avg. Two Year Performance

No purchase track record

No sale track record

Last Three Months:

0 Net Amount

Buy:	0	--
Sell:	0	--